Welcome to our dedicated page for Innate Pharma S.A. ADS news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma S.A. ADS stock.
Innate Pharma S.A. (Symbol: IPHA) is a clinical-stage biotechnology company at the forefront of cancer treatment innovation. Specializing in immuno-oncology, Innate Pharma develops first-in-class therapeutic antibodies designed to harness the innate immune system. This pioneering approach helps the body's natural defenses recognize and combat cancer cells more effectively.
The company's diverse pipeline includes four clinical-stage antibodies along with several preclinical candidates. Key products under development include lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401, and IPH6501. These therapies aim to address a wide range of cancer types, particularly those with high unmet medical needs.
Innate Pharma has made significant strides in the discovery and development of checkpoint inhibitors, leveraging its deep understanding of natural killer cell biology. This expertise has led to strategic partnerships with renowned biopharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi.
The company’s revenue streams primarily come from research collaborations, licensing agreements, and milestone payments from its pharmaceutical partners. Innate Pharma's proprietary platform, ANKET (Antibody-based NK cell Engager Therapeutics), forms the backbone of its innovative therapeutic strategies.
With a commitment to advancing cancer treatment, Innate Pharma continues to make significant progress in clinical trials and research, aiming to bring transformative therapies to patients worldwide.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) will host a virtual investor event on June 23, 2021, at 2 p.m. CEST to discuss key data from its Phase 2 TELLOMAK trial of lacutamab, an anti-KIR3DL2 antibody for T-cell lymphomas. This data will be preceded by a presentation at the 16th International Conference on Malignant Lymphoma on June 22. Additionally, preclinical data on the company’s next-generation NK cell engager platform, ANKET™, will be shared. Registration for the event is required, offering access to dial-in numbers and a replay post-event.
On June 14, 2021, Innate Pharma announced its share structure as of June 1, 2021. The company has a total of 79,027,540 ordinary shares outstanding, along with 6,796 preferred shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights stands at 79,822,040, while the exercisable voting rights are 79,803,465. Innate Pharma focuses on oncology, developing therapeutic antibodies aimed at improving cancer treatment outcomes and is partnered with major biopharmaceutical companies.
Innate Pharma announced significant advancements in its ANKET™ platform, introducing a tetra-specific NK cell engager technology. This innovation, the first of its kind, effectively engages NKp46, CD16, IL-2 variants, and tumor antigens in one molecule. Preclinical data shows strong anti-tumor efficacy and a manageable safety profile in various in vivo tumor models. The company plans to showcase these findings at a virtual IR R&D event on June 23, aimed at enhancing cancer treatment outcomes through synthetic immunity.
Innate Pharma announced the first clinical data of mycosis fungoides from the TELLOMAK trial, which evaluates lacutamab, an anti-KIR3DL2 antibody for T-cell lymphomas. Preliminary data will be presented during the 16th International Conference on Malignant Lymphoma on June 22, 2021, by Dr. Martine Bagot. TELLOMAK, a Phase 2 trial, aims to recruit 150 patients to assess lacutamab's efficacy in advanced T-cell lymphomas. The primary endpoint is objective response rate, with key secondary endpoints including progression-free survival and quality of life.
Innate Pharma SA (Euronext Paris: IPH, Nasdaq: IPHA) conducted its Annual General Meeting (AGM) on May 28, 2021, with 178 votes from 31,717,812 shares, achieving a quorum of 40.14%. All seven Supervisory Board members, including Pascale Boissel, were re-elected. Novo Nordisk A/S's Marcus Schindler opted not to seek re-election due to a new role, but Novo Nordisk remains a shareholder. The AGM recordings and documents are available on the company’s website.
Innate Pharma has announced its total number of outstanding shares and voting rights as of May 1, 2021. The company has 78,997,540 ordinary shares and 79,792,040 theoretical voting rights, which include preferred shares. The number of exercisable voting rights stands at 79,773,465. This disclosure aims to keep the market informed as per AMF regulations. Innate Pharma is focused on oncology treatments and collaborates with major biopharmaceutical companies.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced its Annual General Meeting (AGM) set for May 28, 2021, at 11:00 a.m. CEST, which will be held virtually due to COVID-19 restrictions. Shareholders can vote by post or proxy before May 25. Written questions may be submitted until May 26. The meeting will be accessible via webcast, with voting results communicated during the session. Innate Pharma is focused on oncology and has a diverse pipeline of antibodies aimed at improving cancer treatment outcomes.
Innate Pharma (IPHA) reported progress in its lacutamab TELLOMAK trial, advancing to Stage 2 for KIR3DL2-expressing mycosis fungoides after positive results. The NK cell engager IPH6101 was selected by Sanofi for further development, triggering a €7 million milestone payment. The company reported a cash position of €181.7 million and revenues of €4.5 million for Q1 2021, down from €19.3 million in the same period last year. Innate expects to present additional data from clinical trials later this year.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced a conference call on May 11, 2021, to discuss Q1 2021 business updates. The call will feature CEO Mondher Mahjoubi, CMO Joyson Karakunnel, and CFO Frédéric Lombard. Interested participants can join via webcast or telephone after registering. Innate Pharma focuses on oncology and boasts a diverse pipeline of therapeutic antibodies designed to improve cancer treatment outcomes. Its partnerships with leading biopharmaceutical companies enhance its research capabilities in this sector.
Innate Pharma has filed its 2020 Universal Registration Document with the French AMF and its annual report on Form 20-F with the SEC. Both documents are accessible on the company's website. Innate focuses on oncology with a pipeline of therapeutic antibodies aimed at improving cancer treatments. The company has established significant alliances with major biopharmaceutical firms, enhancing its research capacity. However, the press release warns of risks associated with R&D, clinical trial uncertainties, and potential impacts from COVID-19 on operations.
FAQ
What is the current stock price of Innate Pharma S.A. ADS (IPHA)?
What is the market cap of Innate Pharma S.A. ADS (IPHA)?
What does Innate Pharma S.A. specialize in?
What are some of Innate Pharma's key products?
How does Innate Pharma generate revenue?
Who are some of Innate Pharma's notable partners?
What is ANKET?
What is the focus of Innate Pharma’s current projects?
What stage is Innate Pharma in?
What makes Innate Pharma's approach unique?
What is immuno-oncology?
How does Innate Pharma contribute to cancer research?
